➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Johnson and Johnson
Medtronic
McKesson

Last Updated: April 10, 2021

DrugPatentWatch Database Preview

EISAI INC Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for EISAI INC
International Patents:691
US Patents:32
Tradenames:12
Ingredients:10
NDAs:16
Drug Master File Entries: 1

Drugs and US Patents for EISAI INC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-002 Nov 14, 2008 AB RX Yes No 6,740,669*PED   Start Trial Y   Start Trial
Eisai Inc ARICEPT ODT donepezil hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021720-002 Oct 18, 2004 DISCN Yes No   Start Trial   Start Trial
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-002 Apr 7, 2020 RX Yes Yes 8,268,848   Start Trial Y Y   Start Trial
Eisai Inc FYCOMPA perampanel TABLET;ORAL 202834-002 Oct 22, 2012 RX Yes No 6,949,571   Start Trial Y Y   Start Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 DISCN Yes No 9,169,213   Start Trial   Start Trial
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes   Start Trial   Start Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 DISCN Yes No 8,946,207   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EISAI INC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc ARICEPT donepezil hydrochloride TABLET;ORAL 020690-002 Nov 25, 1996 6,372,760   Start Trial
Eisai Inc BANZEL rufinamide SUSPENSION;ORAL 201367-001 Mar 3, 2011 7,750,028*PED   Start Trial
Eisai Inc ARICEPT donepezil hydrochloride TABLET;ORAL 020690-002 Nov 25, 1996 4,895,841   Start Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 6,469,182   Start Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-003 Nov 14, 2008 7,750,028*PED   Start Trial
Eisai Inc LUSEDRA fospropofol disodium SOLUTION;INTRAVENOUS 022244-001 Dec 12, 2008 6,872,838   Start Trial
Eisai Inc ACIPHEX rabeprazole sodium TABLET, DELAYED RELEASE;ORAL 020973-002 Aug 19, 1999 5,045,552*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for EISAI INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 23 mg ➤ Subscribe 2013-07-09
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2014-06-16
➤ Subscribe Extended-release Tablets 20 mg ➤ Subscribe 2016-12-13
➤ Subscribe Tablets 10 mg ➤ Subscribe 2016-06-27
➤ Subscribe Capsules 4 mg and 10 mg ➤ Subscribe 2019-02-13
➤ Subscribe Tablets 100 mg, 200 mg and 400 mg ➤ Subscribe 2012-11-14
➤ Subscribe Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg ➤ Subscribe 2016-10-24
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2010-06-30

Supplementary Protection Certificates for EISAI INC Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1415987 553 Finland   Start Trial
1300396 420 Finland   Start Trial
1087960 SPC/GB11/039 United Kingdom   Start Trial PRODUCT NAME: ERIBULIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT.; REGISTERED: UK EU/1/11/678/001 20110317; UK EU/1/11/678/002 20110317
0994863 SPC026/2007 Ireland   Start Trial SPC026/2007: 20071026, EXPIRES: 20220115
0994863 CA 2007 00037 Denmark   Start Trial PRODUCT NAME: RUFINAMID, KRYSTALMODIFIKATION A
1300396 12C0074 France   Start Trial PRODUCT NAME: PERAMPANEL, SEL DE CELUI-CI OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/776/001 20120723
1415987 122015000083 Germany   Start Trial PRODUCT NAME: LENVATINIB ODER EINES SEINER PHARMAZEUTISCH AKZEPTABLEN SALZE ODER EINES SEINER HYDRATE; REGISTRATION NO/DATE: EU/1/15/1002/001-002 20150528
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
Merck
AstraZeneca
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.